Capricor Therapeutics’ (CAPR) Buy Rating Reiterated at Maxim Group

Capricor Therapeutics (NASDAQ:CAPR)‘s stock had its “buy” rating restated by Maxim Group in a note issued to investors on Tuesday, Benzinga reports. They currently have a $12.00 price target on the biotechnology company’s stock. Maxim Group’s target price indicates a potential upside of 140.96% from the company’s current price.

Separately, HC Wainwright reissued a “buy” rating and issued a $40.00 target price on shares of Capricor Therapeutics in a research note on Tuesday. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $19.80.

Capricor Therapeutics Price Performance

Capricor Therapeutics stock traded up $0.57 during midday trading on Tuesday, reaching $4.98. The company had a trading volume of 1,201,511 shares, compared to its average volume of 342,339. The company has a market capitalization of $159.26 million, a P/E ratio of -5.78 and a beta of 3.92. Capricor Therapeutics has a 12-month low of $2.68 and a 12-month high of $7.28. The firm’s fifty day simple moving average is $4.33 and its 200-day simple moving average is $5.17.

Capricor Therapeutics (NASDAQ:CAPR) last released its earnings results on Wednesday, August 7th. The biotechnology company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.03). Capricor Therapeutics had a negative return on equity of 220.27% and a negative net margin of 102.93%. The business had revenue of $3.97 million during the quarter, compared to analysts’ expectations of $4.51 million. On average, analysts expect that Capricor Therapeutics will post -1.24 EPS for the current fiscal year.

Institutional Trading of Capricor Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in CAPR. Vanguard Group Inc. increased its holdings in Capricor Therapeutics by 17.2% in the 1st quarter. Vanguard Group Inc. now owns 1,365,903 shares of the biotechnology company’s stock valued at $9,274,000 after purchasing an additional 200,499 shares during the last quarter. Jump Financial LLC acquired a new stake in Capricor Therapeutics in the 4th quarter valued at approximately $258,000. BNP Paribas Financial Markets acquired a new stake in Capricor Therapeutics in the 1st quarter valued at approximately $40,000. Main Street Financial Solutions LLC increased its holdings in Capricor Therapeutics by 37.5% in the 2nd quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock valued at $131,000 after purchasing an additional 7,500 shares during the last quarter. Finally, Marshall Wace LLP acquired a new stake in Capricor Therapeutics in the 2nd quarter valued at approximately $426,000. Institutional investors and hedge funds own 21.68% of the company’s stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.